Liquidity ratios measure the company ability to meet its short-term obligations.
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Assets
- Common-Size Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Solvency Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Capital Asset Pricing Model (CAPM)
- Selected Financial Data since 2005
- Return on Assets (ROA) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Liquidity Ratios (Summary)
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
An analysis of liquidity trends from March 2022 through June 2026 reveals a sustained period of contraction followed by a partial recovery. All three primary liquidity indicators exhibit a high degree of correlation, reflecting a consistent shift in the short-term asset position relative to current liabilities.
- Current Ratio
- The current ratio experienced a gradual decline from a peak of 4.83 in December 2022 to a trough of 2.36 in September 2025. A reversal of this trend is observed starting in December 2025, with the ratio ascending to 3.19 by June 2026.
- Quick Ratio
- The quick ratio mirrored the trajectory of the current ratio, decreasing from 4.46 in December 2022 to a low of 1.84 in September 2025. A subsequent recovery trend is evident in the final three quarters, with the ratio reaching 2.54 by June 2026.
- Cash Ratio
- The most pronounced decline occurred in the cash ratio, which fell from 3.93 in December 2022 to a minimum of 1.40 in September 2025. This indicates a significant reduction in the most liquid assets relative to short-term obligations before a recovery to 1.99 by June 2026.
Despite the substantial decrease in liquidity metrics between 2022 and late 2025, all ratios remained consistently above 1.0. This indicates that the capacity to meet short-term obligations was maintained throughout the period, while the recovery observed in 2026 suggests a strengthening of the overall liquidity position.
Current Ratio
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||
| Current assets | ||||||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||||||
| Liquidity Ratio | ||||||||||||||||||||||||
| Current ratio1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Current Ratio, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The liquidity position of the company exhibited significant volatility over the analyzed period, characterized by an initial phase of high liquidity, a sharp contraction in mid-2024, and a subsequent gradual recovery through June 2026.
- Current Assets Trend
- Current assets showed a steady increase from March 31, 2022, peaking at 14.69 billion US dollars in September 2023. A substantial reduction occurred by June 30, 2024, when assets dropped to 8.94 billion US dollars. Following this trough, a consistent recovery trend was observed, with assets rising to 12.54 billion US dollars by June 30, 2026.
- Current Liabilities Trend
- Current liabilities followed a general upward trajectory, increasing from 2.18 billion US dollars in March 2022 to a peak of 4.47 billion US dollars in June 2025. While there was a slight decrease in the latter part of the period, liabilities remained elevated compared to the 2022 baseline, stabilizing around 3.93 billion US dollars by June 2026.
- Current Ratio Analysis
- The current ratio began at a very high level of 4.75 in March 2022, maintaining levels above 4.0 through September 2023. A notable decline began in early 2024, reaching a low of 2.36 by September 30, 2025. This compression was driven by the simultaneous decrease in current assets and the increase in current liabilities. However, the ratio improved during the final three quarters of the sequence, ending at 3.19 in June 2026.
Despite the downward shift from the initial peaks, the current ratio remained well above 2.0 throughout the entire period. This indicates that the company maintained a substantial cushion of liquid assets to cover its short-term obligations, signifying a strong and sustainable liquidity position even during the period of asset contraction.
Quick Ratio
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||||||
| Marketable securities | ||||||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||||||
| Total quick assets | ||||||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||||||
| Liquidity Ratio | ||||||||||||||||||||||||
| Quick ratio1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Quick Ratio, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The liquidity profile of the organization exhibits a general downward trend in the quick ratio over the analyzed period, moving from a position of exceptionally high liquidity to a more moderate, albeit stable, level. While the quick ratio remains well above 1.0, indicating a consistent ability to meet short-term obligations without relying on inventory, there is a marked shift in the composition of the balance sheet between 2022 and 2026.
- Total Quick Assets Trend
- Quick assets experienced an initial growth phase, peaking at 13,466,900 thousand US$ in September 2023. This was followed by a significant contraction in the second quarter of 2024, where assets dropped to 7,451,600 thousand US$. From June 2024 through June 2026, a gradual recovery phase is observed, with quick assets steadily increasing to reach 9,986,700 thousand US$ by the end of the period.
- Current Liabilities Evolution
- Current liabilities demonstrate a sustained upward trajectory for the majority of the period. Obligations rose from 2,180,200 thousand US$ in March 2022 to a peak of 4,475,300 thousand US$ in June 2025. Following this peak, liabilities stabilized and slightly declined, ending the period at 3,937,900 thousand US$ in June 2026.
- Quick Ratio Performance
- The quick ratio began at a very high level of 4.37 in March 2022, peaking at 4.46 in December 2022. A consistent decline followed, characterized by a sharp drop between March 2024 (3.15) and June 2024 (2.10). The ratio reached its lowest point of 1.84 in September 2025. However, the final three quarters show a recovery trend, with the ratio climbing back to 2.54 by June 2026.
The overall analysis suggests a period of significant capital reallocation or expenditure occurring in early 2024, which coincided with the sharpest decline in the quick ratio. Despite the reduction from the initial peaks, the organization maintains a strong liquidity cushion, as the quick ratio remains consistently above 1.80 throughout the entire period, ensuring sufficient liquid assets to cover current liabilities.
Cash Ratio
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||||||
| Marketable securities | ||||||||||||||||||||||||
| Total cash assets | ||||||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||||||
| Liquidity Ratio | ||||||||||||||||||||||||
| Cash ratio1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Cash Ratio, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
An analysis of the liquidity position from March 31, 2022, to June 30, 2026, reveals a significant shift in the company's cash management strategy and overall liquidity profile. The period is characterized by an initial phase of high liquidity accumulation, followed by a sharp contraction in cash assets in mid-2024, and a subsequent period of gradual recovery.
- Total Cash Assets Trend
- Cash holdings exhibited steady growth from March 2022, rising from 8.24 billion to a peak of 11.93 billion by September 30, 2023. A substantial reduction occurred between March 31, 2024, and June 30, 2024, where assets decreased from 10.17 billion to 5.80 billion. Following this decline, cash levels entered a recovery phase, trending upward to reach 7.85 billion by June 30, 2026.
- Current Liabilities Trajectory
- Current liabilities demonstrated a consistent upward trend for the first several years, increasing from 2.18 billion in March 2022 to a peak of 4.48 billion in June 2025. Unlike the volatility seen in cash assets, the growth in liabilities was more linear, though a slight contraction occurred toward the end of 2025, stabilizing around 3.94 billion by June 2026.
- Cash Ratio Dynamics
- The cash ratio, which measures the ability to cover short-term obligations with the most liquid assets, peaked at 3.93 in December 2022. A sustained decline followed, accelerating sharply in June 2024 to 1.63. The ratio reached its lowest point of 1.40 in September 2025. Since that low, the ratio has improved steadily, closing at 1.99 in June 2026.
- Liquidity Assessment
- Despite the volatility and the significant drop in the cash ratio between 2022 and 2025, the company maintained a cash ratio above 1.0 throughout the entire reporting period. This indicates that the company consistently held sufficient cash and cash equivalents to satisfy all current liabilities without relying on the sale of inventory or the collection of receivables.